Dear PIQ Hot Copper Members,I had a few questions that were...

Dear PIQ Hot Copper Members,

I had a few questions that were asked and I endeavoured to ask as many as possible without taking the AGM into technocratic oblivion.

Specifically about the Current Procedural Terminology (CPT codes) reimbursement code, a "Specialist Group" has been engaged to consult with Insurer's, Laboratories, and GP's who would order the test via different focus groups. They are also doing an "Economic Health Benefit Study" and another study (missed the exact title but it involved doctors and how the test would improve the quality of care for their patients). I know that these things are obvious to you and me but from a bureaucratic perspective reports are what the American Medical Association (AMA) use when they create a new code.
To me it sounded like while there was a lot of work being done on getting the CPT code, this other information will be used to determine relevant pricing to maximise testing via Insurer's buy in and GP's understanding the patient benefit (as it is the GP relationship with the patient that is critical to a test being ordered). On the other side of the equation are the Laboratories that want a high $ test for their own cost / profit requirements.
PIQ is moving its Immunoassay production from TGR BioSciences in SA to Europe. My guess would be to Expedeon AG's facility in Cambridge UK as they now own TGR BioSciences and that would be an easier technology transfer to a much larger production facility.
It will be these IA kits manufactured at the European facility that will be submitted to the FDA for approval. No dates provided for submission, though as others have suggested, I would expect that a submission would not be made until after the Jansen Stage 2 Study results due early 2021.
The Giardia work has been slowed significantly as there have been border lockdowns that have stopped the travel to Australia from primarily Bali and other SE Asian countries of people who have the parasite. It is still a priority research area in need of infected patients.
Regarding Atturos, the OCProDx Prostrate Cancer test is their test and not part of the PIQ intellectual property. Atturos are involved in PIQ work to the extent that MS Tests are done not IA. I expect that this need will disappear soon though Richard was optimistic that Mass Spectrometry testing was the future of Proteomics once the systems were developed to speed up the workflows.
Omnics Global Solutions is still marketing the Promarker D test in the Dominican Republic though as Richard pointed out there has basically been only one test that everyone has been focused on for the past 10 months.
Finally to the question of live streaming the AGM, it has been considered but at this stage there are no plans for it. It increases the risk significantly for directors who have to then stay exactly to scripted lawyer approved answers to questions. Its not that there is information disclosed to the AGM that other shareholders are not privy to but that an accidental remark that goes un-noticed at a meeting can become the stuff of a lawyers picnic.
I hope that this helps fill some gaps in information or reaffirms current knowledge.

Good luck all holders and I hope I have not misunderstood anything that was being discussed and provided incorrect interpretation of what was discussed.
Like always, information provided on a best endeavours basis.
Cheers,
The Rad